U
GEVA

UBS’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

UBS’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$138K Buy
2,000
+1,020
+104% +$73K ﹤0.01% 5588
2014
Q2 		$103K Sell
980
-390
-28% -$33.2K ﹤0.01% 5911
2014
Q1 		$113K Buy
+1,370
New +$127K ﹤0.01% 5840

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

UBS's GEVA Position: Q3 2014 in Review

UBS increased its SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) stake by 104% in Q3 2014, buying an estimated $73K and bringing the position to 2,000 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #5588.

UBS first reported a position in GEVA in Q1 2014 and has held it in 3 quarters since. 120 funds tracked by Wall St. Rank hold GEVA as of Q3 2014.

  • UBS held 2,000 shares of SYNAGEVA BIOPHARMA CORP COM STK (DE) worth $138K as of Q3 2014.
  • UBS bought 1,020 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q3 2014, an estimated $73K.
  • SYNAGEVA BIOPHARMA CORP COM STK (DE) made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5588 holding.
  • UBS first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2014 and has held it in 3 quarters since.
  • 120 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.